Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorFrancesc Colom, PsyD, PhD

About this trial

This study aims to evaluate the efficacy of a specially developed internet-based Cognitive Behavioural Therapy (CBT) programme with human interaction-referred to as the 3D programme-tailored specifically for women experiencing moderate depressive symptoms. We hypothesise that participation in the intervention will lead to greater improvements in depression severity, compared to receiving only brief psychoeducational videos, when used as an add-on to treatment as usual (TAU) in this population.

The 3D programme is a 10-week blended intervention that includes ten weekly online self-guided modules focused on depression and women's health, along with six individual video sessions with a health/clinical psychologist. The modules cover topics such as mood changes across the menstrual cycle, body image, stress, caregiving, and the impact of gender-based experiences on mental health.

To explore how biological factors may influence how participants respond to treatment, the study will collect biological samples. These will be analysed to track hormone and metabolic changes, with the goal of identifying biological markers that might predict who benefits most from the intervention.

Ultimately, the results of this study aim to improve access to effective and personalised mental health care for women by evaluating whether a structured and personalised online CBT programme can provide meaningful benefits.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women

Age between 18 and 45 years (inclusive)

Moderate depressive symptoms, defined by a score of 17 to 23 on the 17-item Hamilton Depression Rating Scale (HDRS-17)

Fluent in Spanish

Disqualifiers

Currently receiving psychological therapy

Participation in any other interventional clinical trial for depression within the past 3 months

Pregnant or planning to become pregnant during the study period

Cognitive impairment that may interfere with informed consent or study participation

Trial design

Design model

Parallel

Treatments tested in this trial

  • iCBT with human interaction

    Behavioral

    The 3D programme is a 10-week online intervention based on Cognitive Behavioural Therapy (CBT), designed to support women's mental health. Participants will use the 3D website to complete 10 weekly self-guided modules that include videos, written materials, and interactive activities. Topics address depression and issues commonly experienced by women, such as hormonal changes, caregiving, body image, and sexism. All content is available in both video and text formats. Participants will also have six one-to-one video sessions with a trained health/clinical psychologist, who will tailor the programme by recommending specific modules or tasks. All therapists will complete training on the 3D programme and online therapy. Participants will receive guidance on how to use the 3D website before starting.

  • Psychoeducational videos

    Behavioral

    This control arm provides psychoeducational content without therapist support or homework assignments, serving as an adjunct to standard care. This distinguishes it from the experimental arm, which includes therapist-guided interventions and active homework components.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Internet-based Cognitive Behavioural Therapy (iCBT) with human interaction+ Treatment as usual (TAU)Experimental treatment 1 intervention
Group B: Brief psychoeducational videos + TAUActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Depression severity

Change in depressive symptoms, as measured by the 17-item Hamilton Depression Rating Scale (HDRS-17), validated in Spanish. Score range: 0 to 52; higher scores indicate more severe depression.

Time frame
Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline

Secondary outcomes

1

Overall functioning

Change in overall functioning, measured using the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0, 36-item version), self-administered and validated in Spanish.The WHO-DAS 2.0 assesses functioning across six domains. Higher scores indicate greater disability. The Spanish version has demonstrated strong psychometric properties across psychiatric populations.

Time frame
Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline
2

Health-related quality of life

Change in health-related quality of life, assessed using the EQ-5D-5L, a self-reported questionnaire validated in Spanish. The EQ-5D-5L measures five dimensions. Each dimension is rated on a 5-point scale, and responses are combined into a single index score ranging from below 0 (very poor health) to 1 (perfect health). Additionally, a Visual Analogue Scale (VAS) is included, ranging from 0 (worst imaginable health) to 100 (best imaginable health).

Time frame
Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
3

Perceived Stress

Change in perceived stress, measured using the Perceived Stress Scale (PSS-10), a 10-item self-reported questionnaire validated in Spanish. Each item is rated on a 5-point scale from 0 (never) to 4 (very often). Total scores range from 0 to 40, with higher scores indicating greater levels of perceived stress.

Time frame
Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
4

Menstruation-related distress

Change in menstruation-related distress, measured using the Menstrual Distress Questionnaire (MEDI-Q), a 25-item self-reported tool assessing symptoms such as pain, discomfort, psychological changes, gastrointestinal issues, and physiological alterations. The MEDI-Q is a novel instrument and does not yet have a validated Spanish version; this study may contribute to its adaptation for Spanish-speaking populations.

Time frame
Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.

Other outcomes

1

Tryptophan metabolism biomarkers

Quantification of tryptophan and related metabolites (kynurenine, serotonin, 3-hydroxykynurenine, 5-hydroxyindoleacetic acid, kynurenic acid) and calculation of metabolic ratios (e.g., kynurenine/tryptophan ratio) using LC-MS/MS in biological samples (blood, saliva, urine, nails, hair). Higher or altered levels may be associated with treatment response.

Time frame
Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
2

Steroid hormone profile

Changes in hormone production and balance over time associated with intervention participation. Measurement of sex hormones (estradiol, testosterone, progesterone) and glucocorticoids (cortisol, 20α-DHE, 20β-DHE) and their metabolites using LC-MS/MS in biological samples (blood, saliva, urine, nails, hair). Hormonal alterations over time will be evaluated as potential markers of treatment effects.

Time frame
Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Francesc Colom, PsyD, PhD

Lead sponsor

Hospital del Mar Research Institute (IMIM)

Sponsor institution

Instituto de Salud Carlos III

Collaborator

Hospital del Mar

Collaborator